VSM Wealth Advisory LLC Raises Stake in Pfizer Inc. $PFE

VSM Wealth Advisory LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 90.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,104 shares of the biopharmaceutical company’s stock after buying an additional 2,905 shares during the period. VSM Wealth Advisory LLC’s holdings in Pfizer were worth $148,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pacer Advisors Inc. increased its position in Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after buying an additional 17,957,928 shares during the last quarter. Amundi raised its stake in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Nuveen LLC purchased a new stake in Pfizer during the first quarter valued at about $389,861,000. Vanguard Group Inc. boosted its position in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after purchasing an additional 9,041,990 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $25.45 on Wednesday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The company has a fifty day moving average of $24.82 and a 200-day moving average of $24.46. The company has a market capitalization of $144.70 billion, a P/E ratio of 13.54, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Scotiabank initiated coverage on Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.28.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.